| Identification | Back Directory | [Name]
L-Lysinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[4-(hydroxymethyl)phenyl]-N6-(triphenylmethyl)- | [CAS]
1116085-98-3 | [Synonyms]
Fmoc-Phe-Lys(Trt)-PAB
L-Lysinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[4-(hydroxymethyl)phenyl]-N6-(triphenylmethyl)-
L-Lysinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[4-(hydroxymethyl)phenyl]-N6-(triphenylmethyl)- USP/EP/BP | [Molecular Formula]
C56H54N4O5 | [MDL Number]
MFCD34180563 | [MOL File]
1116085-98-3.mol | [Molecular Weight]
863.05 |
| Hazard Information | Back Directory | [Uses]
Fmoc-Phe-Lys(Trt)-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. | [Biological Activity]
Fmoc-Phe-Lys(Trt)-PAB is a cleavable ADC linker that can be used to synthesize antibody drug conjugates (ADCs). | [in vitro]
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. | [target]
| [IC 50]
Protease Cleavable Linker; Cleavable Linker | [References]
[1] Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. DOI:10.1038/nrd.2016.268 |
|
|